Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Research & Development (2016 - 2025)

Historic Research & Development for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $2.0 million.

  • Lisata Therapeutics' Research & Development fell 2293.47% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 1432.83%. This contributed to the annual value of $11.3 million for FY2024, which is 1099.42% down from last year.
  • Per Lisata Therapeutics' latest filing, its Research & Development stood at $2.0 million for Q3 2025, which was down 2293.47% from $2.3 million recorded in Q2 2025.
  • Lisata Therapeutics' Research & Development's 5-year high stood at $3.4 million during Q3 2023, with a 5-year trough of $2.0 million in Q3 2025.
  • Moreover, its 3-year median value for Research & Development was $2.9 million (2024), whereas its average is $2.8 million.
  • The largest annual percentage gain for Lisata Therapeutics' Research & Development in the last 5 years was 195.03% (2024), contrasted with its biggest fall of 2479.29% (2024).
  • Over the past 3 years, Lisata Therapeutics' Research & Development (Quarter) stood at $3.0 million in 2023, then decreased by 2.09% to $2.9 million in 2024, then tumbled by 33.59% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.3 million for Q2 2025, and $2.6 million during Q1 2025.